Novo Nordisk has sued Eli Lilly over national advertising campaigns for the companies' competing weight loss and diabetes drugs, alleging that Lilly is misleading consumers by using older clinical trials to claim its treatments are more effective.The lawsuit, filed Tuesday in U.S
District Court for the Eastern District of Pennsylvania on March 28, where hundreds of similar lawsuits over Ozempic-related gastroparesis have been brought against Novo Nordisk and other manufacturers of GLP-1 receptor agonists, which are a class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound and others, alleging the drug makers failed to adequately warn about the risk of severe gastrointestinal side effects
Some people report a temporary increase in migraine frequency during dose increases, likely linked to dehydration and changes in meal patterns
Get Enough Sleep Prioritize good sleep hygiene
Single-dose Zepbound pens and Zepbound vials will not be covered by the bridge program